TNF and Behcet disease: In a multicenter study of 18 refractory Behcet disease patients with major vessel involvement, including four with pulmonary aneurysms, the 12-month risk of relapse was significantly lower with anti-TNFα compared with conventional immunosuppressants (i.e., cyclophosphamide, azathioprine or methotrexate) in previous treatment lines 6% vs. 41% (p = 0.036) [49].